Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.

"Conflict of Interest Statement BD reports consulting honoraria from Sermo Inc. EBH reports research funding from Merck Serono. CT reports a consulting/advisory role with Accuray. EJK reports grants from National Institutes of Health, Stand Up 2 Cancer, MD Anderson Cancer Center, Philips Healthcare, Elekta, and GE Healthcare; personal fees from RenovoRx and Taylor and Francis; and a consulting/advisory role with Augmenix. ACK reports ownership of shares in Aravive, Inc. PD reports consulting/advisory relationships with the American Society for Radiation Oncology and the National Cancer Institute. All reported conflicts are outside of the submitted work."

"This work was supported in part by Cancer Center Support (Core) grant P30 CA016672 from the National Cancer Institute, National Institutes of Health, to the University of Texas MD Anderson Cancer Center. BD was supported by the RSNA Research & Education Foundation through grant number RR2111. EK was supported by DOD (W81XWH-21-1-0709) and NIH (U54CA210181, U54CA143837, U01CA196403, U01CA200468, U01CA200468, U01CA214263, P50CA221707, R01CA221971, R01CA218004, P30CA016672). EBL was supported by the Andrew Sabin Family Fellowship and the Fund for Innovation in Cancer Informatics."